KALA
KALA BIO, Inc.Company Information
- Company Name
- KALA BIO, Inc.
- CIK
- CIK0001479419
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KALA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KALA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-30
- Last sale
- 2025-10-23
- Shares purchased (TTM)
- 310,559
- Shares sold (TTM)
- 850,936
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 612,634
- Shares outstanding
- 74,159
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-19
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 2 | 8 | 21 | 32 | 42 | 51 | 49 | 54 | 48 | 51 | 56 | ||||||
| Short Term Investments | 7 | 7 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 2 | 3 | 2 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 11 | 12 | 9 | 24 | 34 | 46 | 53 | 51 | 59 | 50 | 53 | 58 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 11 | 12 | 9 | 25 | 36 | 48 | 55 | 54 | 62 | 53 | 56 | 61 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 0 | 1 | 2 | 3 | 4 | 4 | 5 | 4 | 4 | 5 | 6 | 6 | ||||||
| Deferred Income Current | - | - | - | - | - | 1 | 1 | 0 | 2 | - | 1 | 3 | ||||||
| Operating Lease Liability Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt Current | - | - | - | 28 | 10 | 16 | 10 | 18 | 12 | 6 | - | - | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | 2 | 2 | - | - | - | - | - | - | ||||||
| Liabilities Current | 2 | 2 | 2 | 33 | 16 | 23 | 17 | 24 | 19 | 12 | 8 | 10 | ||||||
| Liabilities | 2 | 2 | 2 | 34 | 39 | 43 | 43 | 47 | 48 | 46 | 48 | 50 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 707 | 707 | 702 | 687 | 685 | 683 | 680 | 667 | 665 | 648 | 637 | 632 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Retained Earnings Accumulated Deficit | -698 | -697 | -695 | -696 | -688 | -677 | -668 | -660 | -651 | -641 | -629 | -621 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Noncurrent | - | - | - | 1 | 23 | 20 | 26 | 23 | 29 | 34 | 40 | 40 | ||||||
| Stockholders Equity | 9 | 11 | 7 | -9 | -3 | 6 | 12 | 7 | 14 | 7 | 8 | 11 | ||||||
| Liabilities And Stockholders Equity | 11 | 12 | 9 | 25 | 36 | 48 | 55 | 54 | 62 | 53 | 56 | 61 | ||||||
| Series E Non Redeemable Non Controlling Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | 19 | 15 | 20 | 17 | 23 | 29 | 34 | 34 | ||||||
| Series F Non Redeemable Non Controlling Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | 3 | 3 | 5 | 5 | 4 | 4 | 4 | 4 | ||||||
| Series G Non Redeemable Non Controlling Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Series H Non Redeemable Non Controlling Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Series I Non Redeemable Non Controlling Preferred Stock | - | - | 0 | -0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Series Aa Convertible Non Redeemable Preferred Stock | -1 | 1 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Subsequent Event | - | 19 | - | - | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | 5 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,500 | 1,500 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 19 | 19 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 19 | 19 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKALA BIO, Inc. (KALA) — SEC Financial Statements & Analysis
KALA BIO, Inc. (KALA) is a pharmaceutical preparations company, incorporated in DE. KALA BIO, Inc. trades on Nasdaq as: KALA. KALA BIO, Inc. (KALA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19. Based on that filing, KALA BIO, Inc. carries a market cap of $128.30K, a P/E ratio of -0.01x, a P/B ratio of 0.01x, an enterprise value of $-100.70K, and an EV/EBITDA multiple of 0.00x. On profitability, it posts a Return on Equity (ROE) of -345.32%, a Return on Assets (ROA) of -43.23%, and a Return on Invested Capital (ROIC) of -2137.17%. Per share, it reports EPS of $-135.92, diluted EPS of $-135.92, free cash flow per share of $-267.84, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -72.92% year-over-year, and EPS growth of -52.44% year-over-year. On the balance sheet, it maintains a current ratio of 6.88x, a quick ratio of 4.70x, working capital of $9.04M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.15, an interest coverage ratio of -19.01x, free cash flow of $-19.86M (TTM), and net debt of $-229.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $128.30K
- P/E TTM
- -0.01x
- EPS TTM
- $-135.92
- P/B TTM
- 0.01x
- ROE TTM
- -345.32%
- ROA TTM
- -43.23%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-19.86M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is KALA BIO, Inc. in?
KALA BIO, Inc. (KALA) operates in the Pharmaceutical Preparations industry.
What exchange does KALA trade on?
KALA BIO, Inc. (KALA) trades on the Nasdaq.
Where is KALA BIO, Inc. incorporated?
KALA BIO, Inc. is incorporated in DE.
When was KALA BIO, Inc. (KALA)'s most recent SEC filing?
KALA BIO, Inc. (KALA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19.
What is KALA's market cap?
KALA BIO, Inc. (KALA) has a market capitalization of $128.30K as of 2026-06-30.
What is KALA's EPS (earnings per share)?
KALA BIO, Inc. (KALA)'s trailing twelve month EPS is $-135.92 as of 2026-06-30.
What is KALA's ROE (return on equity)?
KALA BIO, Inc. (KALA)'s trailing twelve month Return on Equity (ROE) is -345.32% as of 2026-06-30.
What is KALA's ROA (return on assets)?
KALA BIO, Inc. (KALA)'s trailing twelve month Return on Assets (ROA) is -43.23% as of 2026-06-30.
What is KALA's ROIC (return on invested capital)?
KALA BIO, Inc. (KALA)'s trailing twelve month Return on Invested Capital (ROIC) is -2137.17% as of 2026-06-30.
What is KALA's EV/EBITDA?
KALA BIO, Inc. (KALA)'s trailing twelve month EV/EBITDA is 0.00x as of 2026-06-30.